Guizhou Xinbang Pharmaceutical Co., Ltd. (002390) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Poor long term growth as Net Sales has grown by an annual rate of -0.84% and Operating profit at -7.54% over the last 5 years

Flat results in Mar 25

With ROE of 2.17%, it has a fair valuation with a 0.93 Price to Book Value

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

CNY 6,314 Million (Mid Cap)

P/E

43.00

Industry P/E

Dividend Yield

1.85%

Debt Equity

-0.02

Return on Equity

2.17%

Price to Book

0.93

Revenue and Profits:

Net Sales:

1,398 Million

(Quarterly Results - Jun 2025)

Net Profit:

89 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

8.84%

6 Months

9.75%

1 Year

-1.25%

2 Years

-19.76%

3 Years

-25.8%

4 Years

-42.48%

5 Years

-41.28%

Guizhou Xinbang Pharmaceutical Co., Ltd. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Guizhou Xinbang Pharmaceutical Co., Ltd. Reports Flat Financial Performance with Notable Profit Growth

Guizhou Xinbang Pharmaceutical Co., Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has recently released its financial results for the quarter ending March 2025. The company has reported a flat financial performance during this period, indicating stability amidst a challenging market environment.

One of the key highlights from the financial report is the significant growth in net profit, which reached CNY 41.24 MM, marking an impressive increase of 62.73% compared to the previous year. This growth in profitability suggests that Guizhou Xinbang Pharmaceutical Co., Ltd. is effectively managing its operations and capitalizing on market opportunities.

Additionally, the company has experienced a decrease in raw material costs, which fell by 2.73% year-over-year. This reduction in costs could potentially enhance the company's margins and ...

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-0.84%

EBIT Growth (5y)

-7.54%

EBIT to Interest (avg)

7.85

Debt to EBITDA (avg)

1.08

Net Debt to Equity (avg)

0.01

Sales to Capital Employed (avg)

0.79

Tax Ratio

17.45%

Dividend Payout Ratio

112.15%

Pledged Shares

Institutional Holding

ROCE (avg)

5.50%

ROE (avg)

4.68%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

0.93

EV to EBIT

24.10

EV to EBITDA

12.86

EV to Capital Employed

0.93

EV to Sales

1.06

PEG Ratio

Dividend Yield

1.85%

ROCE (Latest)

3.87%

ROE (Latest)

2.17%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Mildly Bullish

Dow Theory

Mildly Bearish

No Trend

OBV

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -2.51% vs -1.81% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 64.38% vs 170.00% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,398.40",
          "val2": "1,434.40",
          "chgp": "-2.51%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "154.80",
          "val2": "119.10",
          "chgp": "29.97%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "4.70",
          "val2": "5.80",
          "chgp": "-18.97%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "88.60",
          "val2": "53.90",
          "chgp": "64.38%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "71.90%",
          "val2": "45.20%",
          "chgp": "2.67%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -6.62% vs 1.77% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -55.99% vs 31.87% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "6,007.20",
          "val2": "6,433.40",
          "chgp": "-6.62%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "498.30",
          "val2": "654.00",
          "chgp": "-23.81%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "24.40",
          "val2": "40.50",
          "chgp": "-39.75%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-2.40",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "155.70",
          "val2": "353.80",
          "chgp": "-55.99%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "44.10%",
          "val2": "61.90%",
          "chgp": "-1.78%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

1,398.40

1,434.40

-2.51%

Operating Profit (PBDIT) excl Other Income

154.80

119.10

29.97%

Interest

4.70

5.80

-18.97%

Exceptional Items

0.00

Consolidate Net Profit

88.60

53.90

64.38%

Operating Profit Margin (Excl OI)

71.90%

45.20%

2.67%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is -2.51% vs -1.81% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 64.38% vs 170.00% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

6,007.20

6,433.40

-6.62%

Operating Profit (PBDIT) excl Other Income

498.30

654.00

-23.81%

Interest

24.40

40.50

-39.75%

Exceptional Items

-2.40

0.00

Consolidate Net Profit

155.70

353.80

-55.99%

Operating Profit Margin (Excl OI)

44.10%

61.90%

-1.78%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is -6.62% vs 1.77% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -55.99% vs 31.87% in Dec 2023

All Annual Results

Company CV

About Guizhou Xinbang Pharmaceutical Co., Ltd.

Guizhou Xinbang Pharmaceutical Co., Ltd.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Guizhou Xinbang Pharmaceutical Co., Ltd.

1Day

52 Week

CASH

FII

DII

Promoter

MarketsMojo — Loved in India, Now Global

Dashboard

Poor long term growth as Net Sales has grown by an annual rate of -0.84% and Operating profit at -7.54% over the last 5 years

Flat results in Mar 25

With ROE of 2.17%, it has a fair valuation with a 0.93 Price to Book Value

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Guizhou Xinbang Pharmaceutical Co., Ltd. Reports Flat Financial Performance with Notable Profit Growth

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Annual Results Snapshot (Consolidated) - Dec'24

About Guizhou Xinbang Pharmaceutical Co., Ltd.

Company Coordinates